COMMUNIQUÉS West-GlobeNewswire

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
09/03/2026
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% [...]
The Right to Religious Exemption to Vaccination Upheld in Court, according to the Journal of American Physicians and Surgeons
09/03/2026
TUCSON, Ariz., March 09, 2026 (GLOBE NEWSWIRE) -- Despite concerns about COVID vaccines, vaccine mandates are increasing in hospitals, schools, military service, and even ordinary employment, writes Andrew Schlafly in [...]
LifeMD Reports Fourth Quarter and Full Year 2025 Results
09/03/2026
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral [...]
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
09/03/2026
LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
09/03/2026
– LOQTORZI ® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year [...]
CapsoVision to Participate in the 38th Annual ROTH Conference
09/03/2026
- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology [...]
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
09/03/2026
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation [...]
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
09/03/2026
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class [...]
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
09/03/2026
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 [...]
TrimRx Telehealth Weight Loss Platform Examined in 2026 Consumer Research Report on GLP-1 Medication Access, Pricing Transparency and Safety Considerations
09/03/2026
An Informational Analysis of TrimRx Compounded Semaglutide and Tirzepatide Programs, Telehealth Prescription Process, Published Pricing Disclosures, Pharmacy Partnerships and Patient Safety Information for 2026 San [...]
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
09/03/2026
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 [...]
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
09/03/2026
Anniversary Milestone Highlights Expanded Manufacturing Capacity, Stronger Asia-Pacific Presence, and Measurable Contributions to Global Supply Chain Resilience FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One [...]
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
09/03/2026
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and [...]
Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
09/03/2026
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report [...]
Direct Meds GLP-1 Program Report 2026: Compounded Semaglutide and Tirzepatide Pricing, Telehealth Access, and Consumer Verification Factors
09/03/2026
A 2026 industry overview of the Direct Meds telehealth platform, including its compounded GLP-1 medication access model, pricing structure, delivery formats, consultation process, pharmacy sourcing, and considerations [...]
AEON Biopharma Appoints John Bencich as Chief Financial Officer
09/03/2026
Veteran biotechnology leader with extensive capital markets experience joins AEON as Company advances lead asset through key regulatory milestones IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc [...]
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
09/03/2026
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain [...]
Sherry Cummings, CEO of Gryphon Healthcare, Named One of the Top 50 Women to KNOW in Texas
09/03/2026
HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Sherry Cummings, Chief Executive Officer of Gryphon Healthcare , has been named one of the 2026 Women to KNOW in Texas , a prestigious statewide honor recognizing women who [...]
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
09/03/2026
– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with [...]

Pages